John W. Walsh Alpha-1 Home Infusion Act of 2023
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The John W. Walsh Alpha-1 Home Infusion Act of 2023 is a legislative proposal introduced in the 118th Congress aimed at addressing issues related to home infusion therapy for patients with Alpha-1 antitrypsin deficiency. The bill was referred to the House Subcommittee on Health but did not advance further and is currently classified as failed or expired. Specific provisions, detailed text, and official summary are not available, limiting the ability to provide a comprehensive description of the bill's content or intended mechanisms.
This bill sought to improve home infusion therapy access or regulation for Alpha-1 antitrypsin deficiency patients but did not progress beyond initial referral and is no longer active in the current Congress.
- The bill is focused on health policy, specifically related to Alpha-1 antitrypsin deficiency and home infusion therapy.
- It was introduced in the House of Representatives during the 118th Congress and referred to the Subcommittee on Health.
- No official summary or full bill text is publicly available, and the bill status is failed or expired.
['Patients with Alpha-1 antitrypsin deficiency requiring home infusion therapy', 'Healthcare providers and home infusion service organizations', 'Potentially health insurance programs covering home infusion treatments']
['Lack of publicly available full text and summary limits understanding of implementation requirements and funding mechanisms.', 'Without detailed provisions, oversight and enforcement mechanisms cannot be assessed.', 'Potential cost implications for healthcare payers and providers are unknown.']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health but did not advance further. The failure or expiration status indicates it did not receive a vote or committee report before the end of the congressional session. The absence of detailed public information suggests limited legislative activity or prioritization.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could influence insurance coverage policies for home infusion therapy related to Alpha-1 antitrypsin deficiency.', 'Potentially increased demand for home infusion services and related healthcare infrastructure.', 'Possible shifts in healthcare delivery models for chronic respiratory conditions.']
The absence of an official summary and full bill text limits transparency and public understanding of the bill's scope and impact. This lack of information hinders effective oversight and informed debate. The bill's failure to progress beyond referral suggests limited legislative momentum or prioritization during the 118th Congress.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.